載入...

Denosumab in Postmenopausal Osteoporosis: What the Clinician Needs to Know

Denosumab is a subcutaneously (SC) administered investigational fully human monoclonal antibody to receptor activator of nuclear factor-kB ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal mediator of osteoclastic bone resorption. RANKL stimulates the format...

全面介紹

Na minha lista:
書目詳細資料
主要作者: Lewiecki, E. Michael
格式: Artigo
語言:Inglês
出版: SAGE Publications 2009
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382669/
https://ncbi.nlm.nih.gov/pubmed/22870424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X09343221
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!